A5019429833- CAR-T cell therapy research
- Pituitary Gland Disorders and Treatments
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Nanowire Synthesis and Applications
- Knee injuries and reconstruction techniques
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Acute Myocardial Infarction Research
- Shoulder Injury and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Osteoarthritis Treatment and Mechanisms
- Growth Hormone and Insulin-like Growth Factors
- Anesthesia and Pain Management
- Immune cells in cancer
- Atrial Fibrillation Management and Outcomes
- RNA Interference and Gene Delivery
- Tendon Structure and Treatment
- Periodontal Regeneration and Treatments
- Meningioma and schwannoma management
- Nanoplatforms for cancer theranostics
- Total Knee Arthroplasty Outcomes
Sichuan University
2016-2025
West China Hospital of Sichuan University
2010-2025
State Key Laboratory of Biotherapy
2021-2023
Beijing Tsinghua Chang Gung Hospital
2023
Tsinghua University
2023
West China Medical Center of Sichuan University
1999-2022
Tianjin Medical University General Hospital
2022
Capital Medical University
2022
Beijing Anzhen Hospital
2022
Zhejiang Chinese Medical University
2022
Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as novel therapeutic target for GBM chimeric antigen receptor (CAR) T cell therapy. In this study, CAR targeting was constructed and transduced into cells by lentivirus. Antitumor effects B7-H3-specific CAR-T were assessed lines both vitro vivo. Our results indicated that positively...
Glioblastoma (GBM) is the most aggressive primary malignant brain cancer and urgently requires effective treatments. Chimeric antigen receptor T (CAR-T) cell therapy offers a potential treatment method, but it often hindered by poor infiltration of CAR-T cells in tumors highly immunosuppressive tumor microenvironment (TME). Here, we armed an oncolytic adenovirus (oAds) with chemokine CXCL11 to increase reprogram TME, thus improving its therapeutic efficacy. In both immunodeficient...
Purpose: Given that heterogeneous expression and variants of antigens on solid tumors are responsible for relapse after chimeric antigen receptor (CAR)-T cell therapy, we hypothesized combinatorial targeting two tumor-associated would lessen this problem enhance the antitumor activity T cells. Methods:The co-expression level CD70 B7-H3 was analyzed in multiple tumor tissue samples.Further, putative were identified The Cancer Genome Atlas Gene Expression Profiling Interactive Analysis...
Recently, B7-H3 was frequently reported to be overexpressed in various cancer types and has been suggested a promising target for immunotherapy. In the present study, we analyzed mRNA expression of The Cancer Genome Atlas (TCGA) database validated its across multiple types. We then generated novel B7-H3-targeted chimeric antigen receptor (CAR) tested antitumor activity both
Background Rotator cuff tears are common, affecting more than 60% of individuals older 80 years, and they have been implicated in 70% patients with shoulder pain. M1 polarization-related inflammation has reported to be associated poor healing outcomes rotator injury, leptin, an adipokine, a potential activator inflammation. However, whether leptin affects repair remains unknown. Questions/purposes Using vitro cell experiments vivo rat tear model, we therefore asked: (1) Does promote the...
Abstract Objective We conducted a first‐in‐human study to evaluate the bioactivity and safety of B7‐H3‐targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma. Methods Tumor tissues from patient with meningioma were evaluated B7‐H3 expression. CAR‐T delivered into intracranial tumor resection cavity using an Ommaya device at maximum dose 1.5 × 10 7 cells. Magnetic resonance imaging (MRI) screening multiple serum indexes regularly monitored....
Numerous options for treatment of glioblastoma have been explored; however, single-drug therapies and poor targeting failed to provide effective drugs. Chemotherapy has significant antitumor effect, but the efficacy in clinic is limited over a long period time. Thus, novel therapeutic approaches are necessary address these critical issues.The present study, we investigated tumor-specific metal-tea polyphenol-based cascade nanoreactor chemodynamic therapy-enhanced chemotherapy.HA-EGCG was...
Abstract Background Chimeric antigen receptor (CAR) T cells and immune checkpoint blockades (ICBs) have made remarkable breakthroughs in cancer treatment, but the efficacy is still limited for solid tumors due to tumor heterogeneity microenvironment. The restrained treatment prompted us seek new potential therapeutic methods. Methods In this study, we conducted a small molecule compound library screen human BC cell line identify whether certain drugs contribute CAR killing. Signaling...
Craniopharyngioma (CP) is a common refractory tumor of the central nervous system. However, little known about expression and clinical significance B7 family ligands/receptors in CP patients. Thus, we conducted present study to address this issue cohort 132 cases.We mapped quantified molecules programmed cell death ligand 1 (PD-L1), B7-H3, B7-H4 V-domain Ig-containing suppressor T activation (VISTA) 89 adamantinomatous-type 43 papillary-type samples using immunohistochemistry...
Abstract Background Craniopharyngioma (CP) is rare histologically benign but clinically challenging tumor because of its intimate relationship with the critical structure in central brain. CP can be divided into two major histologic subtypes: adamantinomatous-type (ACP) and papillary-type (PCP). Although some genetic aberrations for both categories have been revealed previous studies, complete spectrum changes this remains unknown. Methods In study, we conducted whole genome sequencing (WGS)...
Extranodal nasal natural killer (NK)/T cell lymphoma (ENKTCL) is a rare but highly aggressive subtype of non-Hodgkin (NHL). Nevertheless, despite extensive research, the estimated 5-year overall survival affected patients remains low. Therefore, new treatment strategies are needed urgently. Recent advances in immunotherapy have potential to broaden applications chimeric antigen receptor-modified T (CAR-T) cells and bispecific T-cell engaging (BiTE) antibody. Here, we screened panel...
Tendon-to-bone healing is a complex and slow process, the rate of poor remains high. In recent years, several new strategies have been developed that enhance tendon-to-bone by increasing bioactivity. Fibrin clots widely used to improve tissue engineering,Modified fibrin can bioactivity tendon-bone interface histological appearance.Controlled laboratory study.A total 27 male New Zealand White rabbits were used. Of these, 3 for cell isolation, remaining 24 divided into 2 groups (12 per group)...
T cell-engaging therapies involving bispecific cell engager (BiTE) and chimeric antigen receptor (CAR-T) cells have achieved great success in the treatment of hematological tumors. However, paucity ideal surface molecules that can be targeted on glioblastoma (GBM) partially reduces immunotherapeutic efficacy. Recently, high expression Fn14 has been reported several solid tumors, so strategy exploiting this specific for GBM immunotherapy is worth studying. Consequently, we constructed Fn14×...
Targeting cancer antigens by T cell-engaging bispecific antibody (BiAb) or chimeric antigen receptor cell therapy has achieved successes in haematological cancers, but attempts to use them fight solid cancers have been disappointing, part due escape. MEK inhibitor had limited activity as a single agent, enhanced antitumor when combined with other therapies, such targeted drugs immunotherapy agents. This study aimed analyze the expression of B7-H3 non-small-cell lung (NSCLC) and bladder (BC)...
Background Despite advances in B7 homolog 3 protein (B7-H3) based immunotherapy, the development of drug resistance remains a major clinical concern. The heterogeneity and emerging loss B7-H3 expression are main causes treatment failure targeted therapies, which reveals an urgent need to elucidate mechanism underlying regulation expression. In this study, we identified explored crucial role transcription factor SPT20 (SP20H) tumor progression. Methods Here, performed CRISPR/Cas9-based genome...